Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD

Mellon-Reppen, S.; Ratanatharathorn, Voravit; Cronin, Simon; Uberti, Joseph P.

doi:10.1038/bmt.2010.58

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Mellon-Reppen et al [27] showed that using repeated courses of rituximab is feasible and effective in cases of recurrent nephrotic syndrome-associated cGVHD. This finding also suggests a possible role for chronic administration of rituximab as maintenance; however, such approach will need to balance treatment benefit against the potential risks associated with long-term administration of rituximab, particularly development of prolonged cytopenias [28] and serious infections.…”

Section: Rituximab For Corticosteroid-refractory Chronic Gvhdmentioning

confidence: 98%

See 1 more Smart Citation

Rituximab for prevention and treatment of graft-versus-host disease

Kharfan‐Dabaja

Cutler

2011

Int J Hematol

View full text Add to dashboard Cite

Growing understanding of the important role of B lymphocytes in alloreactivity has paved the way for evaluating anti-B cell therapy with rituximab in patients undergoing allogeneic hematopoietic cell transplantation. Data suggesting a beneficial reduction in incidence and severity of acute graft-versus-host disease (GVHD) are limited to non-randomized studies from single institutions using higher than conventional doses of rituximab. Additionally, rituximab is used as an effective treatment of corticosteroid-refractory chronic GVHD with good responses, particularly in cases of dermatologic and mucosal involvement. Post-transplant administration of rituximab appears to reduce the rate of chronic GVHD in preliminary studies.

show abstract

Section: Rituximab For Corticosteroid-refractory Chronic Gvhdmentioning

confidence: 98%

“…n number of subjects, ORR overall response rate, BSA body surface area a Meta-analysis did not include data from Refs [21,25,27]. b Pooled proportion c Organ specific-responses shown only if C4 patients assessed…”

mentioning

confidence: 99%

Rituximab for prevention and treatment of graft-versus-host disease

Kharfan‐Dabaja

Cutler

2011

Int J Hematol

View full text Add to dashboard Cite

show abstract

Glomerular Diseases Associated With Chronic Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation: Case Reports

Chanswangphuwana

Townamchai

Intragumtornchai

et al. 2014

Transplantation Proceedings

View full text Add to dashboard Cite

Recent Progress in Managing Graft-Versus-Host Disease and Viral Infections Following Allogeneic Stem Cell Transplantation

Sellar

Peggs

2012

Future Oncol.

View full text Add to dashboard Cite

Despite recent reductions in transplant-related mortality, post-transplant complications such as graft-versus-host disease (GvHD) remain major obstacles to the successful application of allogeneic hematopoietic transplantation. Steroid-refractory GvHD has a poor outcome. Although there are a variety of new approaches to the treatment of refractory GvHD, many have limited evidence of efficacy. Other approaches appear to be unacceptably toxic. It would be preferable to improve GvHD prophylaxis. There is good evidence that rates of GvHD can be reduced without unacceptable reduction of the graft-versus-leukemia effect or compromising overall survival. However, prophylactic measures aimed at reducing T-cell numbers or functions are associated with high rates of reactivation of latent viruses. New technologies that allow rapid generation of virus-specific T-cells show promise to reduce the frequency and severity of such reactivations and have the potential to revolutionize the approach to post-transplant infectious complications.

show abstract

Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD

Cited by 4 publications

References 9 publications

Rituximab for prevention and treatment of graft-versus-host disease

Rituximab for prevention and treatment of graft-versus-host disease

Glomerular Diseases Associated With Chronic Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation: Case Reports

Recent Progress in Managing Graft-Versus-Host Disease and Viral Infections Following Allogeneic Stem Cell Transplantation

Contact Info

Product

Resources

About